Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

Clinical and Experimental Allergy

Volumn 33, Issue 12, 2003, Pages 1641-1647

  Pajno, G B ^a,d   Vita, D ^a   Parmiani, S ^b   Caminiti, L ^a   La Grutta, S ^c   Barberio, G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b ALK Abello Group   (Italy)

^c Children Hospital   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Children; Early skin response; Fluticasone; Late skin response; Parietaria pollen; Sublingual immunotherapy; Visual analog score

Indexed keywords

FLUTICASONE PROPIONATE; IMMUNOLOGIC AGENT; POLLEN ANTIGEN;

ADOLESCENT; ALLERGIC ASTHMA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PARIETARIA; POLLEN ALLERGY; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; SEASONAL VARIATION; SKIN SENSITIZATION; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADMINISTRATION, INHALATION; ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ALLERGENS; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; COMBINED MODALITY THERAPY; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PARIETARIA; PLANT PROTEINS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SKIN; TREATMENT OUTCOME;

EID: 0348107381     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2003.01809.x     Document Type: Article

References (28)

1. Bousquet J, Lockey RE, Mailing HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 1998; 53 (Suppl. 44): 1-42.
2. Bousquet J, Van Cauwemberge P, Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA). J Allergy Clin Immunol 2001; 108 (Suppl. 5):S147-334.
3. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine-mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.
4. +T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messanger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65.
5. +) cells accompany inhibition of allergen induced late skin responses following successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99:254-60.
6. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-75.
7. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995; 5:25-30.
8. Passalacqua G, Albano M, Riccio A et al. Clinical and immunological effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1999; 104:964-8.
9. Purello D'Ambrosio F, Gangemi S, Isola S et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999; 54:968-73.
10. D'Ambrosio FP, Ricciardi L, Isola S et al. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996; 24:146-51.
11. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998; 9:116-24.
12. EAACI. Position paper. Allergy 1993; 48 (Suppl. 14):17.
13. Carreira J, Rubio M, Herrero T et al. Collaborative clinical assay of the biological potency of allergen skin tests extracts. Clin Allergy 1984; 14:503-7.
14. Carreira J, Lombardero M, Ventas P. New developments in vitro methods. Quantification of clinically relevant allergens in mass units. Arbeiten aus dem Paul Ehrlich Institut.Gustav Fischer Verlag, Stuttgart, 1994.
15. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-3.
16. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mites by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7.
17. Purello D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31:1295-302.
18. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
19. Berger WE, Ford LB, Mahr T et al. Efficacy and safety of fluticasone dipropionate 250 μg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol 2002; 89:393-9.
20. Von Berg A, Gappa M, Steinkamp G, Flit-DNCG Study Group. Fluticasone for the treatment of symptomatic bronchial asthma in children treated with sodium chromoglycate - a prospective, randomised trial. Eur J Med Res 2002; 7:257-64.
21. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol (Madr) 1990; 18:277-84.
22. Vourdas D, Syrigou E, Potamianou P et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53:662-72.
23. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002; 57:297-305.
24. Garcia Villalmanzo I, Hernandez MD, Campos A et al. Immunotherapy with a mass unit Parietaria judaica extract: a tolerance study with evidence of immunological changes to the major allergen Par j 1. J Investig Allergol Clin Immunol 1999; 9:321-9.
25. Varney VA, Gaga M, Frew AJ et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-9.
26. Nish WA, Charlesworth EN, Davis TL. The effect of immunotherapy on the cutaneous late response to antigen. J Allergy Clin Immunol 1994; 93:484-93.
27. Parker WA Jr, Whisman BA, Apoliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84:667-77.
28. Torres Lima M, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-14.